Actinogen Medical Limited · ASX:ACW
Actinogen Medical — Investor Presentation (March 2017)
25 slides from Actinogen Medical's investor presentation, Mar 27, 2017
Slide 1: Latest Investor Presentation
Latest Investor Presentation For personal use only Sydney, 27 March 2017: Actinogen Medical (ASX: ACW) is pleased to attach its latest Investor Presentation slide-deck, which is available on the “Investor Centre” section of Actinogen’s website. Investors can also click on the following link to acces
Slide 2: About XanADu
About XanADu XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem, in subjects with mild dementia due to Alzheimer’s disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the U
Slide 3: Investor Presentation
For personal use only INVESTOR PRESENTATION Dr Bill Ketelbey CEO March 2017
Slide 4: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Actinogen Medical Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all inform
Slide 5: Overview
For personal use only 3 OVERVIEW
Slide 6: A devastating disease
For personal use only A A lzheimer’s disease is the leading cause of death in the UK and Europe and the second leading DEVASTATING cause of death in Australia. DISEASE Of the top-ten leading fatal illnesses, it remains the only one that cannot be prevented, treated or cured. Drugs available to treat
Slide 7: Corporate Overview
CORPORATE OVERVIEW Actinogen Medical (ASX:ACW) is focused on an For personal use only innovative approach for treating Alzheimer's STOCK METRICS* disease and cognitive impairment in chronic neurodegenerative diseases, through the inhibition of cortisol production. • The Company is developing Xanamem
Slide 8: A Simple But Compelling Story
A SIMPLE BUT COMPELLING STORY For personal use only 1 2 3 4 5 Xanamem™ - a Independent research Human trial of cortisol Xanamem™ Phase I human trials novel therapy for shows a strong inhibition in the brain demonstrated a confirm that Xanamem™ Alzheimer's disease that association between demonstrate
Slide 9: Board of Directors
BOARD OF DIRECTORS For personal use only DR GEOFF BROOKE CHAIRMAN Dr Brooke is a clinically trained physician turned venture capitalist with over 30 years' experience in the healthcare investment industry. He was the founder and managing director of two venture capital firms, Medvest Inc and GBS Ven
Slide 10: Xanamem Clinical Advisory Board
XANAMEMTM CLINICAL ADVISORY BOARD For personal use only PROFESSOR CRAIG RITCHIE (CHAIR) Professor Ritchie is a world-leading authority on dementia and has been a senior investigator on more than 30 drug trials of both disease-modifying and symptomatic agents for the condition. Professor Ritchie is l
Slide 11: Market Opportunity and About Xanamem
For personal use only MARKET OPPORTUNITY AND ABOUT XANAMEM™ 9
Slide 12: Alzheimer's Disease: A Vast Unmet Medical Need
ALZHEIMER’S DISEASE: A VAST UNMET MEDICAL NEED For personal use only • There are nearly 50 million Alzheimer's disease sufferers world-wide and the number is set to double every 20 years. • It’s the leading cause of death in the UK and second only to heart disease in Australia. • Of the top-ten lead
Slide 13: Why There Is Vast Market Potential for Xanamem
WHY THERE IS VAST MARKET POTENTIAL FOR XANAMEM™ For personal use only • The incidence and cost of treating Alzheimer’s is growing rapidly. Management of Alzheimer's will swamp available budgets. • There are currently only four approved drugs to treat Alzheimer’s, none of which modify the underlying
Slide 14: The Current State of AD Drugs in Development
THE CURRENT STATE OF AD DRUGS IN DEVELOPMENT • There are around 100 different compounds in human research for Alzheimer's disease. For personal use only • Xanamem is only one of two cortisol inhibitors under development. • Xanamem will be used in combination with other drugs under development. • Xan
Slide 15: About Xanamem
ABOUT XANAMEMTM For personal use only Actinogen Medical’s research candidate, Xanamem™, is a novel drug under development for the treatment of Alzheimer’s disease. • Research has demonstrated that increased cortisol, also known as the “stress hormone”, is associated with cognitive impairment, the de
Slide 16: Validation
VALIDATION For personal use only CORTISOL and ALZHEIMER’S: • A number of recent independent studies support the association between cortisol and the development and progression of Alzheimer's disease. (Geerlings et al 2015, Lehallier et al 2015, Popp et al 2015, Ennis et al 2017, Peitrzak et al 2017
Slide 17: Clinical Development
For personal use only CLINICAL DEVELOPMENT 15
Slide 18: Historical Timeline
HISTORICAL TIMELINE For personal use only Carbenoxolone is shown to 11ẞ-HSD1 is highly enhance cognitive function expressed in regions in elderly men and type II important for diabetics S TA R T Xanamem™ cognition (Sandeep et al., 2004) data publication 11ẞ-HSD1 First First Xanamem™ and enzyme paten
Slide 19: XanADu Phase II Trial
XANADU PHASE II TRIAL For personal use only Phase II double blind, randomised, placebo-controlled study to assess the efficacy and safety of Xanamem™ in participants with mild Alzheimer's disease XanamemTM treatment course 12 weeks 174 Mild Alzheimer’s patients XanamemTM 10mg daily for 12 weeks Vs T
Slide 20: Diseases Being Targeted with Xanamem
DISEASES BEING TARGETED WITH XANAMEMTM For personal use only PRE-CLINICAL PHASE I PHASE II Alzheimer’s disease Diabetes cognitive impairment Post traumatic stress disorder Post myocardial infarction 18
Slide 21: Valuation and Outlook
For personal use only VALUATION AND OUTLOOK 3 19
Slide 22: Peer Comparison
PEER COMPARISON For personal use only What big pharma 2000 companies are paying 1800 for acquisition of drug 1600 VALUE US$ MILLIONS developers in the 1400 Alzheimer’s space X 1200 1000 800 X 600 X 400 200 0 PH I PH II PH III 20
Slide 23: Xanamem's Journey of Discovery
XANAMEM™’S JOURNEY OF DISCOVERY For personal use only Diabetes Cognition Phase II 11β-HSD1 is highly expressed in regions XanADu First Subject In important for cognition Xanamem™ data Carbenoxolone is shown to enhance published cognitive function in Webster et al., 2017 11β-HSD1 elderly men and Firs
Slide 24: Investment Summary
INVESTMENT SUMMARY For personal use only Huge unmet medical Novel approach: The Multiple Potential XanamemTM has a Highly experienced need: The total cost of association between Indications: Actinogen long patent life: Board and Alzheimer’s to rise to $US cortisol and Alzheimer’s has identified a nu
Slide 25: Contact
For personal use only CONTACT: DR. BILL KETELBEY CEO & Managing Director ☏ Main: +61 2 8964 7401 ✉Email: bill.ketelbey@actinogen.com.au
Actinogen Medical — Investor Presentation (March 2017) on 6ix